The leading Chronic Myeloid Leukemia Companies such as Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, ...

Focusing on the initiation of treatment for newly diagnosed patients with CML, Jorge E. Cortes, MD, details important factors to consider when starting treatment and Claire Saxton discusses strategies ...

Shares of Enliven Therapeutics (NASDAQ:ELVN) climbed 7% on Thursday after the company released positive early results from a ...

Dr Lindsay Rein comments on significant advancements in CML treatment presented at ASH 2024, particularly the approval of asciminib in both the frontline and second-line settings. This new treatment ...

Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic mutations and imatinib failure, and dasatinib with a switch to imatinib.

The survival prognosis for patients with chronic phase CML has greatly improved since the introduction of TKIs, with some studies showing life expectancy close to the general population. Nonetheless, ...

Terns Pharmaceuticals climbed by 629.64 percent in 2025, primarily boosted by stellar results from the clinical trial of its ...

Please provide your email address to receive an email when new articles are posted on . In this video, Eric Winer, MD, discusses the results of research into chronic myeloid leukemia presented at ASCO ...

Treatment-free remission (TFR) may be feasible in many patients with chronic myeloid leukaemia (CML), say researchers who set out clinical and logistical requirements for discontinuing tyrosine kinase ...

Shares of Enliven Therapeutics were sharply higher after the biotechnology company reported positive initial data from a Phase 1b trial for a leukemia treatment. The stock was up 61% at $24.95 in ...

Alembic Pharmaceuticals Ltd has obtained tentative approval from the USFDA for its Bosutinib tablets, used to treat specific ...